Natixis Grows Position in Kenvue Inc. (NYSE:KVUE)

Natixis grew its stake in Kenvue Inc. (NYSE:KVUE - Free Report) by 29.3% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 315,489 shares of the company's stock after purchasing an additional 71,545 shares during the period. Natixis' holdings in Kenvue were worth $6,736,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Handelsbanken Fonder AB raised its holdings in shares of Kenvue by 2.9% during the 4th quarter. Handelsbanken Fonder AB now owns 742,184 shares of the company's stock worth $15,846,000 after acquiring an additional 21,222 shares during the period. Alberta Investment Management Corp raised its stake in Kenvue by 23.2% during the fourth quarter. Alberta Investment Management Corp now owns 582,895 shares of the company's stock worth $12,445,000 after purchasing an additional 109,700 shares during the period. Longbow Finance SA boosted its holdings in Kenvue by 5.0% in the 4th quarter. Longbow Finance SA now owns 280,568 shares of the company's stock valued at $5,990,000 after purchasing an additional 13,287 shares during the last quarter. Steward Partners Investment Advisory LLC boosted its holdings in Kenvue by 143.1% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 47,938 shares of the company's stock valued at $1,023,000 after purchasing an additional 28,216 shares during the last quarter. Finally, CORDA Investment Management LLC. grew its stake in shares of Kenvue by 1.4% in the 4th quarter. CORDA Investment Management LLC. now owns 1,253,096 shares of the company's stock valued at $26,754,000 after buying an additional 17,466 shares during the period. Institutional investors and hedge funds own 97.64% of the company's stock.

Kenvue Stock Up 1.2 %

Shares of Kenvue stock traded up $0.28 during trading on Friday, hitting $23.03. 22,249,578 shares of the stock were exchanged, compared to its average volume of 17,101,628. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. The firm's 50-day moving average price is $23.01 and its 200 day moving average price is $22.42. The stock has a market cap of $44.19 billion, a price-to-earnings ratio of 43.45, a price-to-earnings-growth ratio of 2.62 and a beta of 1.02. Kenvue Inc. has a 12-month low of $17.67 and a 12-month high of $24.46.

Kenvue (NYSE:KVUE - Get Free Report) last issued its earnings results on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, hitting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. As a group, analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, May 28th. Investors of record on Wednesday, May 14th will be given a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.56%. The ex-dividend date is Wednesday, May 14th. Kenvue's dividend payout ratio (DPR) is 154.72%.

Analysts Set New Price Targets

A number of research analysts recently commented on KVUE shares. Redburn Atlantic assumed coverage on Kenvue in a report on Thursday, April 10th. They issued a "neutral" rating and a $23.50 price objective on the stock. UBS Group cut their price objective on Kenvue from $23.00 to $21.00 and set a "neutral" rating for the company in a research report on Friday, February 7th. Barclays decreased their target price on shares of Kenvue from $23.00 to $22.00 and set an "equal weight" rating on the stock in a research report on Monday, April 14th. Canaccord Genuity Group lifted their price target on shares of Kenvue from $24.00 to $29.00 and gave the company a "buy" rating in a research report on Wednesday, March 5th. Finally, Citigroup upped their price objective on shares of Kenvue from $21.00 to $22.00 and gave the stock a "neutral" rating in a report on Monday, April 14th. Eight analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, Kenvue has a consensus rating of "Hold" and a consensus target price of $24.42.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.